← Oncology Approval Tracker

FDA DECISION ·

Nubeqa

darolutamide · Bayer Healthcare Pharmaceuticals

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic castration-sensitive prostate cancer receiving androgen deprivation, without a requirement for docetaxel.

LAMPGEN ANALYSIS

Why it matters

The indication allows darolutamide plus androgen deprivation without the chemotherapy required in the previous metastatic castration-sensitive indication.

What research teams should watch

Record whether androgen deprivation is pharmacologic or surgical and assess how a non-docetaxel regimen affects patient visits.

PRIMARY RECORDS

Sources